Focused on developing targeted therapies for cancer, Celcuity Inc. is a clinical-stage biotechnology company leveraging its proprietary CELsignia platform to identify new indications for existing drugs. Investors track its progress due to potential breakthroughs in treating breast cancer and other solid tumors through novel signaling pathway analysis.
1 member of Congress has disclosed 4 trades in Celcuity Inc. (CELC), a Healthcare company. The buy/sell breakdown shows 3 purchases versus 1 sale, indicating net buying interest from lawmakers. All data is sourced from STOCK Act periodic transaction reports filed with Congress.
| Date | Politician | Type | Amount |
|---|---|---|---|
| 2021-05-26 | Tom Malinowski | sell | $1K – $15K |
| 2020-06-23 | Tom Malinowski | buy | $1K – $15K |
| 2020-06-22 | Tom Malinowski | buy | $1K – $15K |
| 2020-06-18 | Tom Malinowski | buy | $1K – $15K |